CAS: 500-89-0; 1-(4-Butoxyphenyl)-3-[4-(Dimethylamino)Phenyl]Thiourea
该化合物是具有硫尿亚功能组特征的有机化合物,该功能组由硫磺原子结为碳原子,该原子也同时与氧原子同时存在.该化合物有两种不同的芳香环:一个含有丁氧基的环,另一个含有二甲基氨基组,有助于其溶解性和再活性.丁氧基组的存在增强了其缺水特性,而二甲基氨基组则可以参与各种化学反应,包括质子反应,使该化合物在染料,制药等各种应用中或作为有机合成的中间体中具有潜在用途.该化合物一般在室内温度下是固体的,在标准条件下可能具有中等稳定性,尽管在处理时应谨慎处理与硫尿衍生物有关的潜在毒性.在实验室环境中与该物质打交道时应采取适当的安全措施.
- 英文名称1-(4-Butoxyphenyl)-3-[4-(Dimethylamino)Phenyl]Thiourea
- 中文名称硫安布新
- IUPAC名称1-(p-Butoxyphenyl)-3-(p-dimethylaminophenyl)-2-thiourea
- 其它别名Carbanilide,4-butoxy-4'-(dimethylamino)thio- (6CI,7CI,8CI); 1-(p-Butoxyphenyl)-3-(p-dimethylaminophenyl)-2-thiourea; Thiambutosin; Thiambutosine
- CAS编号500-89-0
- MFCD编号:MFCD00867641
- EINECS号:207-914-0
- FDA UNII编号:X92J960C7P
- 分子式:C19H25N3OS分子量:343.49
- 产品CID: 1488144
- 产品分类原料药 → 人工合成抗感染类药 → 抗结核麻风分支杆菌类药
物理性质
MSDS等安全信息
- 警示词Warning
- 危险描述H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- 防范说明P264Thoroughly clean after treatmentP280Wear protective gloves/Wear protective clothing/Wear protective goggles/Wear a protective maskP305If it enters the eyesP351Rinse carefully with water for a few minutesP338Remove the contact lens(If any)And easy to operate,Continue flushingP337If eye irritation persistsP313Obtain medical advice/care
- 安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
上下游产品
CAS号99-98-9 对氨基-N,N-二甲基苯胺 | CAS号3460-50-2 1-丁氧基-4-异硫氰酰基苯 | CAS号4344-55-2 4-丁氧基苯胺合成工艺路线路线简述
📜4-丁氧基苯胺 反应生成 硫安布新
参考文献:Di-Phenyl-Thioureas
标题:Di-Phenyl-Thioureas
海关参考信息
- 2905121000-正丙醇
2905130000-正丁醇
2908199090-其他酚的卤化衍生物
2908999090-其他酚的硝化衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:CN-102862984-A
优先权日:2012-09-25
标 题:Excess carbon disulfide recovery device and recovery method in the synthesis process of rubber vulcanization accelerator diphenylthiourea
专利号:CN-102350349-A
优先权日:2011-08-29
标 题 :Catalyst used in the oxygen oxidation synthesis production process of accelerator diphenylguanidine and its preparation method
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Smith TC, Richardus JH. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era. Int J Lepr Other Mycobact Dis. 1994 Sep;62(3):353-8. 83(5):447-54. doi: 10.1080/00034983.1989.11812371. 10(2):71-5. 56(20):1364-70. German. 53(2):278-84. 49(4):324-6. 49(2):101-13. 1(6106):133-6. doi: 10.1136/bmj.1.6106.133.
9: Waters MF, Pearson JM, Rees RJ. Drug resistant leprosy--a comparison between proven dapsone and proven thiambutosine resistance. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):152-3. 44(1-2):123. 111(5):651-5. doi: 10.1164/arrd.1975.111.5.651. 100(1188):178-81. doi: 10.1039/an9750000178. 42(5):667-72.
14: Garrod JM, Ellard GA. Appearance of resistance during prolonged treatment of leprosy with Thiambutosine. Lepr Rev. 1968 Jul;39(3):113-7. doi: 10.5935/0305-7518.19680021. 37(1):47-8. doi: 10.5935/0305-7518.19660011. 37(1):17-22. doi: 10.5935/0305-7518.19660003.
合成参考文献
摘要:Guru Prasad AR, Rao VS. Polarographic determination of certain cephalosporins in pharmaceutical preparations. Res Pharm Sci. 2010 Jan;5(1):57–63.
摘要:Smith TC, Richardus JH. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era. Int J Lepr Other Mycobact Dis. 1994 Sep;62(3):353–8.
📝 需求与反馈
尽可能描述清楚需求与问题信息
